Evidence receipt / belief
Published · transcript-backedDavid Rosenthal: belief
22 Jan 2024 Acquired Novo Nordisk (Ozempic)
“Yup. I suspect it's probably both. I do think Danish culture plays into this too.”
Source trail
Everything needed to verify it.
- Speaker
- David Rosenthal
- Attribution
- Verified speaker
- Claim type
- belief
- Recorded
- 22 Jan 2024
- Publisher
- Acquired
- Episode
- Novo Nordisk (Ozempic)
Transcript context
…Yeah, you have to actually be aligned with the owners so you get the fruit of the appreciation or the punishment if it doesn't do well. Yup. I suspect it's probably both. I do think Danish culture plays into this too. It is a much, much more socialist country than America. Actually, watching interviews with Lotte, she talks about this. Sometimes she's asked about it. Hey, didn't you get rich on basically inventing GLP-1s? She's like, no, I've never asked for a raise in my life. I'm a socialist, but look at what we've done for the world. Yeah, it's pretty crazy. The question is, does that thinking lead to the GLP-1 breakthrough? Other pharma companies certainly didn't make these investments in these decisions on these time horizons. There's a reasonable narrative that it was actually Norvo Nordisk's focus and their time horizon that led to the decades long work to actually bear fruit. Semaglutide isn't out of nowhere. It was built on all the work that went into liraglutide since the early 90s and incorporated all the clever ideas they had, previously developing longer acting Insulins and things like that. There is a reasonable narrative of it's their long time horizon and their focus, their ability to learn from doing the same thing well, and iterating them over a hundred years, that actually led them to find this breakthrough when others didn't.…
Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.